Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Xilio Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Xilio Therapeutics, Inc.’s stock price such as:

• Xilio Therapeutics, Inc.’s current stock price and volume
• Why Xilio Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for XLO from analysts
• XLO’s stock price momentum as measured by its relative strength

About Xilio Therapeutics, Inc. (XLO)

Before we jump into Xilio Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Want to learn more about Xilio Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Xilio Therapeutics, Inc..

Xilio Therapeutics, Inc.’s Stock Price as of Market Close

As of May 14, 2025, 12:31 PM, CST, Xilio Therapeutics, Inc.’s stock price was $0.950.

Xilio Therapeutics, Inc. is down 17.37% from its previous closing price of $1.150.

During the last market session, Xilio Therapeutics, Inc.’s stock traded between $0.950 and $1.070. Currently, there are approximately 74.70 million shares outstanding for Xilio Therapeutics, Inc..

Xilio Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Xilio Therapeutics, Inc. Stock Price History

Xilio Therapeutics, Inc.’s (XLO) price is currently up 24.11% so far this month.

During the month of May, Xilio Therapeutics, Inc.’s stock price has reached a high of $1.180 and a low of $0.660.

Over the last year, Xilio Therapeutics, Inc. has hit prices as high as $1.700 and as low as $0.620. Year to date, Xilio Therapeutics, Inc.’s stock is down 0.49%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Xilio Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 13, 2025, there were analysts who downgraded Xilio Therapeutics, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Xilio Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Xilio Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Xilio Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Xilio Therapeutics, Inc. (XLO) by visiting AAII Stock Evaluator.

Relative Price Strength of Xilio Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 13, 2025, Xilio Therapeutics, Inc. has a weighted four-quarter relative price strength of -3.45%, which translates to a Momentum Score of 44 and is considered to be Average.

Want to learn more about how Xilio Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Xilio Therapeutics, Inc. Stock Price: Bottom Line

As of May 14, 2025, Xilio Therapeutics, Inc.’s stock price is $0.950, which is down 17.37% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Xilio Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.